Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Probio-Tec ABCG-Stick-25
- Development stage
- Phase 2
- Lead developer
- Chr. Hansen
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Probio-Tec ABCG-Stick-25 is a multi-strain probiotic dietary supplement developed by Chr. Hansen (now part of Novonesis). The formulation is characterized by the 'ABCG' acronym, which represents four specific, well-documented probiotic strains: *Lactobacillus acidophilus* (LA-5), *Bifidobacterium animalis* subsp. *lactis* (BB-12), *Lactobacillus casei* (L. casei 431), and *Lactobacillus rhamnosus* (LGG). These strains are delivered in a 'stick pack' (sachet) format with a potency of 25 billion colony-forming units (CFU). The product is designed to support gastrointestinal health and immune function through several mechanisms, including the competitive exclusion of pathogenic bacteria, the production of organic acids (such as lactic acid) that lower intestinal pH, and the modulation of the host's immune system via interactions with gut-associated lymphoid tissue (GALT). It is commonly used to maintain a balanced gut microbiota and may be utilized in the management of conditions such as antibiotic-associated diarrhea and irritable bowel syndrome.
- Brand names
- Probio-Tec ABCG-Stick-25
- Other names
- ABCG probioticProbio-Tec ABCG
Beyond the preview
Go deeper on Probio-Tec ABCG-Stick-25.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Probio-Tec ABCG-Stick-25.